RPTP Profile — Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals is a biopharmaceutical company engaged in developing and commercializing therapeutics that treat debilitating and often fatal diseases. Co.'s product includes: PROCYSBI® (cysteamine bitartrate) delayed-release capsules, for the management of nephropathic cystinosis in adults and children six years and older. Co.'s other clinical-stage product candidates include RP103, which contains, cysteamine bitartrate, and utilizes Co.'s proprietary capsule formulation containing delayed-release enteric coated microbeads of cysteamine bitartrate. Co.'s preclinical candidates include include RP105 and RP 106 being developed for a range of rare diseases.